DIOSynVax, a biotech spinout of the University of Cambridge, will receive $42 million (about £32 million) from the Coalition for Epidemic Preparedness Innovations (CEPI) to develop a vaccine candidate that could provide protection against both existing and future variants of SARS-CoV-2 – the virus that causes COVID-19 – as well as other major coronaviruses, including those that cause SARS and MERS. Source: CEPI press release 8/3/22